Abstract
When requesting a blood level measurement in the context of "Therapeutic drug monitoring" (TDM), numerous aspects have to be considered in the pre-analytical and analytical area, as in the integration of associated clinical data. This review presents therapeutic classes for which a clinical benefit of TDM is established or suggested, at least in some settings. For each class of drugs, the main pharmacokinetic, pre-analytical, analytical and clinical aspects are evaluated in the scope of such a monitoring. Each step of the TDM process is important and none should be neglected. Additional clinical trials are however warranted to better establish the exact conditions of use for such a monitoring.
MeSH terms
-
Anti-Bacterial Agents / blood
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Retroviral Agents / blood
-
Anti-Retroviral Agents / pharmacokinetics
-
Anticonvulsants / blood
-
Anticonvulsants / pharmacokinetics
-
Antineoplastic Agents / blood
-
Antineoplastic Agents / pharmacokinetics
-
Antiparasitic Agents / blood
-
Antiparasitic Agents / pharmacokinetics
-
Antitubercular Agents / blood
-
Antitubercular Agents / pharmacokinetics
-
Cardiovascular Agents / blood
-
Cardiovascular Agents / pharmacokinetics
-
Dose-Response Relationship, Drug
-
Drug Monitoring / methods*
-
Drug Monitoring / standards*
-
Evidence-Based Medicine
-
Humans
-
Immunosuppressive Agents / blood
-
Immunosuppressive Agents / pharmacokinetics
-
Product Surveillance, Postmarketing
-
Psychotropic Drugs / blood
-
Psychotropic Drugs / pharmacokinetics
Substances
-
Anti-Bacterial Agents
-
Anti-Retroviral Agents
-
Anticonvulsants
-
Antineoplastic Agents
-
Antiparasitic Agents
-
Antitubercular Agents
-
Cardiovascular Agents
-
Immunosuppressive Agents
-
Psychotropic Drugs